Time between medicine authorization and patient access in Europe 2023, by country

Average time between marketing authorization and patient access for medicines in Europe as of 2023, by country

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2023

Region

Europe

Survey time period

as of January 5, 2023

Supplementary notes

Patient access is defined for most countries as the point at which the product gains access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme.
* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not take into account France's system of temporary authorization for some products, which means this time will be higher than in reality.
***MHRA’s Early Access to Medicines Scheme provides access prior to marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Pharmaceutical trends in Europe "

Other statistics that may interest you Pharmaceutical trends in Europe

Overview

6

Leading companies

7

Employment

6

R&D / Clinical trials / Approvals

8

Self-medication market

6

Further related statistics

17
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.